StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Leerink Partners Reiterates Outperform on BioMarin Pharma (BMRN) Following Mixed Ph. 3 Data Results
March 21, 2016 1:17 PM
Leerink Partners reiterated an Outperform rating on BioMarin Pharmaceutical ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
BioMarin's (BMRN) Pegvaliase Likely to Receive FDA Approval Amid Recent Mixed Data - Wedbush
March 22, 2016 6:32 AM
Pre-Open Stock Movers 03/21: (VAL) (HOT) (MRKT) Higher; (AFFX) (VRX) (BMRN) Lower (more...)
March 21, 2016 9:30 AM
BioMarin Pharma's (BMRN) Pegvaliase Phase 3 PRISM-2 Met Primary Endpoint
March 21, 2016 6:11 AM
BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
March 21, 2016 6:00 AM
Biotechs Continue to Underperform (IBB)
March 17, 2016 10:28 AM
